REGMF Stock Chart & Stats
$10.22
$1.99(20.95%)
At close: 4:00 PM EDT
$10.22
$1.99(20.95%)
Day’s Range― - ―
52-Week Range$5.06 - $16.02
Previous CloseN/A
Volume500.00
Average Volume (3M)90.00
Market Cap
$8.00B
Enterprise Value$36.22K
Total Cash (Recent Filing)$5.14B
Total Debt (Recent Filing)$310.96M
Price to Earnings (P/E)11.0
Beta2.80
Next Earnings
Nov 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)10.37
Shares Outstanding208,581,240
10 Day Avg. Volume40
30 Day Avg. Volume90
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)9.84
Price to Sales (P/S)10.96
P/FCF Ratio-253.57
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$14.86Price Target Upside45.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)0.95
Revenue Forecast (FY)$947.33M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthThe sharp TTM revenue increase indicates substantially stronger product demand or commercialization performance. If sustained, this expansion can improve operating leverage, support pipeline investment, and strengthen RemeGen’s competitive position.
ProfitabilityStrong gross and net margins provide greater capacity to fund research, regulatory work, and commercialization internally. This improves resilience for a biotech company and could reduce dependence on external financing if margins remain durable.
Cash GenerationPositive operating and free cash flow, together with high conversion from earnings, indicates that recent profits are translating into usable liquidity. Sustained cash generation would support pipeline development and reduce financing pressure.
Bears Say
Earnings VolatilityThe rapid shift from substantial losses to very high profitability makes current earnings harder to compare and forecast. Such volatility raises the risk that recent performance reflects an unstable stage of the biotech business rather than a durable baseline.
Cash Flow ConsistencyAlthough TTM cash generation improved sharply, the long history of cash burn and weak 2025 cash flow shows limited consistency. Recurring investment needs or operating setbacks could again require external funding and constrain strategic flexibility.
Balance Sheet InstabilityCurrent leverage appears manageable, but the large year-to-year changes indicate that funding requirements and capital structure can shift quickly. A return to higher borrowing could increase financial risk if profitability or cash generation weakens.
RemeGen Co. Ltd. Class H News
REGMF FAQ
What was RemeGen Co. Ltd. Class H’s price range in the past 12 months?
RemeGen Co. Ltd. Class H lowest stock price was $5.06 and its highest was $16.02 in the past 12 months.
What is RemeGen Co. Ltd. Class H’s market cap?
RemeGen Co. Ltd. Class H’s market cap is $8.00B.
When is RemeGen Co. Ltd. Class H’s upcoming earnings report date?
RemeGen Co. Ltd. Class H’s upcoming earnings report date is Nov 04, 2026 which is in 52 days.
How were RemeGen Co. Ltd. Class H’s earnings last quarter?
RemeGen Co. Ltd. Class H released its earnings results on Aug 24, 2026. The company reported $1.239 earnings per share for the quarter.
Is RemeGen Co. Ltd. Class H overvalued?
According to Wall Street analysts RemeGen Co. Ltd. Class H’s price is currently Undervalued.
Does RemeGen Co. Ltd. Class H pay dividends?
RemeGen Co. Ltd. Class H does not currently pay dividends.
What is RemeGen Co. Ltd. Class H’s EPS estimate?
RemeGen Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RemeGen Co. Ltd. Class H have?
RemeGen Co. Ltd. Class H has 208,581,240 shares outstanding.
What happened to RemeGen Co. Ltd. Class H’s price movement after its last earnings report?
RemeGen Co. Ltd. Class H reported an EPS of $1.239 in its last earnings report. Following the earnings report the stock price went down -6.195%.
Which hedge fund is a major shareholder of RemeGen Co. Ltd. Class H?
Currently, no hedge funds are holding shares in REGMF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
RemeGen Co. Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.97%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
77.57%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
RemeGen Co. Ltd. Class H
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People’s Republic of China.
REGMF Stock 12 Month Forecast
Average Price Target
$14.86
▲(45.39% Upside)
Technical Analysis
Akeso, Inc.
―
Alphamab Oncology
―
InnoCare Pharma Ltd.
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―
Ownership Overview
―
Insiders
3.92% Mutual Funds
― Other Institutional Investors
87.99% Public Companies and
Individual Investors